Journal of the European Academy of Dermatology and Venereology最新文献

{"title":"Atopic dermatitis in the French cohort CONSTANCES (PreDDA study): Focus on persistence and remission in adulthood.","authors":"Khaled Ezzedine, Virginie Hourblin, Sophie Connétable, Fabrice Ruiz, Abdlekrim Ziad, Amélie Sobczak, Sofiane Kab, Adeline Renuy, Marcel Goldberg, Marie Zins, Audrey Nosbaum","doi":"10.1111/jdv.20595","DOIUrl":"https://doi.org/10.1111/jdv.20595","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two cases of cerebrovascular accidents following the induction dose of risankizumab.","authors":"Algün Polat Ekinci, Ahmet Alperen Çevik, Rodi Sari Polat, Fatma Kübra Gül","doi":"10.1111/jdv.20608","DOIUrl":"https://doi.org/10.1111/jdv.20608","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High prevalence of extracutaneous involvement in ITG junctional epidermolysis bullosa.","authors":"Julie Bonigen, Fabienne Charbit-Henrion, Stéphanie Leclerc-Mercier, Jean-Marc Rosenthal, Anne-Claire Bursztejn, Romain Berthaud, Julie Steffan, Christine Chiaverini, Smail Hadj-Rabia, Christine Bodemer","doi":"10.1111/jdv.20579","DOIUrl":"https://doi.org/10.1111/jdv.20579","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International consensus statement on the use of ultrasound in hidradenitis suppurativa.","authors":"X Wortsman, F Alfageme, V Dini, F J García-Martínez, R D Caposiena Caro, J Frew, C Gonzalez, I H Hamzavi, I Kohli, P K Krajewski, M Kuyumllian, J Liu, A Mandava, G Nazzaro, E O'Brien, T Oranges, M Pelizzari, J Rezende, J Romani, R Sigrist, E Taleb, L Zattar, J Zavariz, A Martorell","doi":"10.1111/jdv.20600","DOIUrl":"https://doi.org/10.1111/jdv.20600","url":null,"abstract":"<p><strong>Background: </strong>So far, the evidence on the use of ultrasound (US) in hidradenitis suppurativa (HS) demonstrates the utility of US in the diagnosis, scoring and assessment of HS; however, to date, there is no international consensus statement on the use of US in HS, and several published guidelines do not include this topic.</p><p><strong>Objectives: </strong>To create an international consensus statement on using US in HS that can cover and validate relevant aspects.</p><p><strong>Methods: </strong>A three-round Delphi study with a panel of international experts representing four continents and working with US in HS in their daily practice. The inclusion criteria of the experts and the set of questions in the survey were defined by a steering committee. A consensus of recommendation was defined when the percentage of agreement (sum of strongly agree and agree) was ε 70%. In between 50% and 69% of agreement, a suggestion was considered. Lower than 50% meant no consensus.</p><p><strong>Results: </strong>Twenty-four international experts from 14 countries participated in the study. A high percentage of consensus (96.4%) was achieved for important aspects of the use of US in HS, including the ultrasonographic indications, technical considerations, training, diagnostic criteria, staging systems, monitoring, support of US-guided procedures and planning of surgery, and the need for US in research and clinical trials.</p><p><strong>Conclusions: </strong>An international group of experts created a consensus statement with validated recommendations on the use of US in HS. Despite the challenges of the implementation of ultrasound in HS, this task force highly recommends the use of US in HS.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simulated daylight vs. conventional PDT for clinical superficial BCC: A randomized controlled trial.","authors":"Alexandra Sjöholm, Eva Backman, Maja Modin, Julia Fougelberg, Magdalena Claeson, John Paoli","doi":"10.1111/jdv.20602","DOIUrl":"https://doi.org/10.1111/jdv.20602","url":null,"abstract":"<p><strong>Background: </strong>Photodynamic therapy (PDT) is a recognized treatment for superficial basal cell carcinoma (sBCC). Conventional PDT (C-PDT) has a relatively high clearance rate but is time-consuming and painful. Simulated daylight PDT (SDL-PDT) has the potential advantage of causing less pain, but its effectiveness has not been investigated thoroughly.</p><p><strong>Objectives: </strong>To determine whether SDL-PDT is non-inferior to C-PDT in the treatment of clinically diagnosed sBCC and to assess adverse events during treatment and patient preferences.</p><p><strong>Methods: </strong>In this single-centre, non-inferiority, randomized controlled trial, adult patients with sBCCs of any size and located on anatomical sites suitable for PDT were recruited. Lesions were randomized to two sessions of either SDL-PDT or C-PDT using aminolevulinic acid as the photosensitizer. Patient-perceived pain was measured using a numeric rating scale (NRS) ranging from 0 to 10. Self-report forms were used to measure patient preferences. Patients were evaluated after 3 months to assess early treatment failure and after 1 year to determine overall clearance rates.</p><p><strong>Results: </strong>In total, 78 participants with 193 sBCCs were treated. Most lesions (47.2%) were located on the trunk and were diagnosed solely through dermoscopic evaluation (64.2%). After 1 year, the clearance rate was 62.4% for SDL-PDT and 91.8% for C-PDT (p < 0.001) disproving non-inferiority. Illumination was reported to be more painful during C-PDT (mean NRS score of 3.5 at session 1 and 3.7 at session 2) compared with SDL-PDT (mean NRS score of 0.1 at both sessions) (p < 0.001). Immediately after treatment, 87.5% of respondents expressed a preference for SDL-PDT.</p><p><strong>Conclusions: </strong>SDL-PDT is less effective than C-PDT but is also less painful. Due to the lower clearance rate, this study does not support SDL-PDT as a primary treatment option for sBCC. The randomized controlled trial was registered at http://www.researchweb.org/ (project 264721).</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme.","authors":"B King, P Mirmirani, K Lo Sicco, Y Ramot, R Sinclair, L Asfour, K Ezzedine, C Paul, M Ohyama, R A Edwards, G Bonfanti, U Kerkmann, D Wajsbrot, R Ishowo-Adejumo, S H Zwillich, A Lejeune","doi":"10.1111/jdv.20547","DOIUrl":"https://doi.org/10.1111/jdv.20547","url":null,"abstract":"<p><strong>Background: </strong>Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, demonstrated efficacy over 48 weeks in patients with alopecia areata (AA) in the ALLEGRO phase 2b/3 study.</p><p><strong>Objectives: </strong>This post hoc analysis evaluated individual Severity of Alopecia Tool (SALT) score trajectories in patients who received ritlecitinib 50 mg and rolled over from Phase 2b/3 into the ongoing, open-label, Phase 3 ALLEGRO-LT study to describe long-term response patterns and associated baseline disease characteristics.</p><p><strong>Methods: </strong>Patients aged ≥12 years with ≥50% scalp hair loss received ritlecitinib 50 mg once daily in both studies. SALT score trajectories from baseline to Month 24 were used to categorise patients as early (SALT score ≤20 at Week 24 and Months 12 and 24), middle (≤20 at Months 12 and 24) or late responders (≤20 by Month 24) or as partial responders (maintained 30% improvement), relapsers (achieved but did not maintain 30% improvement) or non-responders (did not achieve 30% improvement). The proportions of patients achieving sustained response (achieved and maintained SALT score ≤20 at all subsequent available time points through Month 24) and complete response (SALT score 0 at ≥1 time point through Month 24) were evaluated. Multivariable logistic regression assessed variables associated with response.</p><p><strong>Results: </strong>Of 191 patients treated with ritlecitinib 50 mg, 87 (45.5%) were responders (SALT score ≤20), 24 (12.6%) were partial responders, 24 (12.6%) were relapsers and 56 (29.3%) were non-responders. Of 87 patients categorised as responders, 81 (93.1%) sustained their clinical response and 47 (46.0%) achieved complete response. Factors associated with treatment response included female sex and less extensive and shorter duration of hair loss.</p><p><strong>Conclusions: </strong>Approximately 45% of patients were SALT score responders, with up to 11% requiring >1 year of ritlecitinib treatment to achieve response, highlighting the importance of extended treatment duration.</p><p><strong>Clinicaltrials: </strong></p><p><strong>Gov registration: </strong>ALLEGRO phase 2b/3 study (NCT03732807); ALLEGRO-LT study (NCT04006457).</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of risk factors affecting the use of oral JAK inhibitors in hidradenitis suppurativa.","authors":"Ditte Georgina Zhang, Johan Sieborg, Valdemar Wendelboe Nielsen, Lea Krog Nymand, Farzad Alinaghi, Jacob P Thyssen, Alexander Egeberg, Julia-Tatjana Maul, Simon Francis Thomsen, Nikolaj Holgersen","doi":"10.1111/jdv.20594","DOIUrl":"https://doi.org/10.1111/jdv.20594","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143408946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prurigo Control Test reflects the severity of itch and skin lesions in patients with chronic prurigo: Data from a real-world study.","authors":"C Zeidler, L S Stahl, S Ständer, J Loewenthal, K Weller, P Salameh, M Metz, M P Pereira","doi":"10.1111/jdv.20582","DOIUrl":"https://doi.org/10.1111/jdv.20582","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143408950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to 'EuroGuiderm guideline on lichen sclerosus-Treatment of lichen sclerosus'.","authors":"G Kravvas, R Watchorn, A Spencer, C B Bunker","doi":"10.1111/jdv.20596","DOIUrl":"https://doi.org/10.1111/jdv.20596","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoprofiling to guide treatment decision in SAM syndrome.","authors":"Olivia Bochnig, Thomas Giese, Judith Fischer, Katalin Komlosi, Silvia Mihalceanu, Hagen Ott, Knut Schäkel","doi":"10.1111/jdv.20597","DOIUrl":"https://doi.org/10.1111/jdv.20597","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}